DEVELOPMENT OF DICLOFENAC SODIUM MATRIX TABLETS EMPLOYING KOLLIDON SR AND PEG 6000 FOR COLON TARGETTED DRUG DELIVERY

The Matrix Tablets each containing 50 mg of diclofenac sodium are prepared employing kollidonSR by direct compression method. The hardness of the tablets was in the range of 6-7kg/sq.cm. Weight loss in friability test was less than 0.3% in all the cases. All the matrix tablets prepared contained 100 ± 2.3% of the labelled claim. All the tablets were found to be non-disintegrating in acidic (pH1.2) and alkaline (pH 7.4) fluids. As such, the prepared tablets were of good quality with respect to drug content, hardness and friability. As the tablets formulated were non- disintegrating in acidic and alkaline fluids, they are considered suitable for colon targeting. From the drug release study it may be concluded that the (DK2) P2 formula of diclofenac sodium matrix tablets have given the desired release profile by showing a minimal release during the lag period of 5 hrs and complete release at the end of 12 hrs. The tablets having the optimised formula (DK2) P2, having 25% kollidonSR with 5% of channelling agent (PEG 6000) showed minimal release of 46% in the lag period of 5 hours and 99.6 % of the drug was released y the end of 12hours. The diclofenac sodium matrix tablets formulated by employing kollidonSR and channelling agent showed non-fickian diffusion mechanism and following zero order kinetics. The optimized formula (DK2) P2 follows Supercase II transport as mechanism for drug release and it follows zero order kinetics. Matrix tablets (DK2) P2 formulated employing 25% kollidonSR and 5% PEG 6000 are best suited to be used for colon targeting of diclofenac sodium